TABLE 1.

Baseline characteristics of children with lymphoma in Lilongwe, Malawi, June 2013 to March 2016

	All (n = 121)	BL (n = 100)	HL (n = 21)
Male, n (%)	84 (69)	66 (66)	18 (86)
HIV status, n (%)
Negative	113 (93)	94 (94)	19 (91)
Positive	2 (2)	2 (2)	0
Unknown	6 (5)	4 (4)	2 (10)
Clinical stage, n (%)
Stage I/II	36 (30)	23 (23)	13 (62)
Stage III	49 (40)	47 (47)	2 (10)
Stage IV	36 (30)	30 (30)	6 (29)
Age in years, median (IQR)	10.1 (7.1–13)	9.4 (7–13)	11.5 (8.3–13.2)
Primary site, n (%)
Abdominal only	56 (46)	48 (48)	8 (38)
Facial only	28 (23)	28 (28)	0
Cervical only	7 (5.8)	2 (2)	5 (24)
Multiple sites	20 (17)	16 (16)	4 (19)
Other	10 (8.3)	6 (6)	4 (19)
Diagnostic specimen, n (%)
Cytology	76 (63)	71 (71)	5 (24)
Histology	45 (37)	29 (29)	16 (76)
B symptoms, n (%)	112 (93)	95 (95)	17 (81)
Duration of symptomatic swelling, n (%)
< 1 month	34 (28)	31 (31)	3 (14)
≥ 1 month	87 (72)	69 (69)	18 (86)
Lansky performance status ≤70, n (%)	94 (78)	82 (82)	12 (57)

BL, Burkitt lymphoma; HL, Hodgkin lymphoma; IQR, interquartile range